Study guide

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites

Key Takeaways Explain This Topic AI

Sudden sniffing death syndrome results from catecholamine sensitization of the myocardium by halogenated hydrocarbons, causing fatal ventricular dysrhythmia during startle or exertion, and can occur on a first exposure.

Because of sudden sniffing death syndrome, catecholamines including epinephrine are avoided where possible in inhalant-related arrest, and beta-blockade is the preferred antidysrhythmic approach.

Chronic toluene exposure causes a distal renal tubular acidosis with a normal anion gap plus profound hypokalemia and muscle weakness, and produces irreversible leukoencephalopathy.

Nitrous oxide irreversibly oxidizes the cobalt in vitamin B12, inactivating methionine synthase and causing subacute combined degeneration with a normal B12 level and an elevated methylmalonic acid.

Alkyl nitrites (poppers) cause methemoglobinemia, treated with methylene blue, and are absolutely contraindicated with phosphodiesterase-5 inhibitors because of fatal hypotension.

Last updated: September 2026

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites

Quick Answer: Inhalants are legal, cheap household and industrial products used for intoxication. Sudden sniffing death syndrome — catecholamine sensitization of the myocardium by halogenated hydrocarbons producing ventricular fibrillation during startle or exertion — can kill on a first use . Toluene causes normal anion gap (distal renal tubular) acidosis with severe hypokalemia and irreversible leukoencephalopathy . Nitrous oxide irreversibly oxidizes cobalamin, inactivating methionine synthase and producing subacute combined degeneration with a normal serum B12 and elevated methylmalonic acid . Alkyl nitrites (poppers) cause methemoglobinemia and are absolutely contraindicated with PDE-5 inhibitors .

Inhalants sit in blueprint category E (other use disorders, 9%, 13 to 15 items) alongside prescription drugs, hallucinogens, designer drugs and process addictions. They are the class most likely to be skipped in preparation and therefore among the highest-yield content per hour studied.

1. The Four Pharmacologic Groups

Group Examples Mechanism Signature toxicity

Volatile solvents Toluene (spray paint, glue, paint thinner), n-hexane, xylene, trichloroethylene, butane, gasoline GABA-A potentiation, NMDA antagonism, membrane fluidization Sudden sniffing death; renal tubular acidosis; leukoencephalopathy; peripheral neuropathy (n-hexane)

Aerosols Computer duster (difluoroethane, tetrafluoroethane), spray deodorant, cooking spray Same as solvents Sudden sniffing death; frostbite injury to face, mouth and airway

Gases Nitrous oxide (whippets, cream chargers, large "Galaxy Gas" style tanks) NMDA antagonism Functional B12 inactivation; asphyxia; frostbite

Alkyl nitrites Amyl, butyl and isobutyl nitrite ("poppers") Nitric oxide donor, smooth muscle relaxation Methemoglobinemia; syncope; retinal toxicity; fatal hypotension with PDE-5 inhibitors

Key distinction: nitrites are used almost exclusively for smooth muscle relaxation and sexual enhancement , not for central intoxication, and their toxicity profile is entirely different from solvents.

2. Sudden Sniffing Death Syndrome

Halogenated and aliphatic hydrocarbons sensitize the myocardium to endogenous catecholamines .

A surge of catecholamines — from being startled, fleeing, or exerting — triggers ventricular tachycardia or fibrillation .

Death can occur on a first exposure , in a healthy adolescent, with no prior warning signs.

Management implications that are directly testable:

Approach a person who is actively inhaling calmly and without startling them .

In inhalant-associated arrest, avoid catecholamines where feasible ; beta-blockade (esmolol) is the preferred approach for hydrocarbon-sensitized dysrhythmia, in contrast to standard protocols.

Teach caregivers that "he only did it once" offers no protection.

  • 3. Toluene: The Two Classic Syndromes
  • Renal tubular acidosis

Chronic toluene inhalation produces a distal (type 1) renal tubular acidosis : normal anion gap metabolic acidosis with severe hypokalemia , often presenting as profound muscle weakness or frank paralysis, sometimes with rhabdomyolysis. Look for the combination of a young patient, paint on the hands or face, weakness, potassium near 2 mEq/L, and a normal anion gap — a normal anion gap is the discriminator from methanol, ethylene glycol and ketoacidosis.

Leukoencephalopathy

Chronic toluene exposure damages cerebral white matter, producing ataxia, tremor, cognitive decline, dysarthria and optic neuropathy , with characteristic MRI white matter changes. These deficits are largely irreversible , which makes early identification and cessation the only effective intervention.

Other solvent-specific injuries

n-Hexane (some glues, rubber cement): distal symmetric peripheral neuropathy through its 2,5-hexanedione metabolite.

Trichloroethylene and carbon tetrachloride : hepatotoxicity and nephrotoxicity.

Benzene (some gasoline products): aplastic anemia and leukemia.

Methylene chloride (paint stripper): metabolized to carbon monoxide , producing delayed and prolonged carboxyhemoglobin elevation.

4. Nitrous Oxide

Nitrous oxide irreversibly oxidizes the cobalt atom in cobalamin, inactivating methionine synthase . The result is a functional B12 deficiency:

  • Finding Expected result
  • Serum B12 Often normal — this is the trap
  • Methylmalonic acid Elevated
  • Homocysteine Elevated

Neurologic picture Subacute combined degeneration — dorsal column and corticospinal tract involvement with paresthesias, loss of vibration and proprioception, ataxia, positive Romberg, spasticity and hyperreflexia

MRI Inverted V sign in the posterior columns of the cervical cord

Treatment: stop exposure, give parenteral B12 , and supplement methionine and folate ; some clinicians add methylcobalamin. Recovery depends on duration of exposure; early treatment can reverse substantial deficit, prolonged exposure often cannot. Large-tank nitrous products sold in convenience stores have driven a marked rise in these presentations.

5. Alkyl Nitrites

Methemoglobinemia: cyanosis unresponsive to oxygen, chocolate-brown blood , a saturation gap between pulse oximetry and measured arterial oxygen saturation. Treat with methylene blue 1 to 2 mg/kg IV (avoid in G6PD deficiency, where ascorbic acid or exchange transfusion is used).

Absolute interaction: nitrites plus PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) produce profound, refractory hypotension. This is a required counseling point for any patient who reports popper use, and it intersects heavily with sexualized stimulant use.

Retinal toxicity: maculopathy with central vision loss has been reported with isopropyl nitrite formulations.

6. Assessment and Treatment

Ask specifically. Inhalant use is rarely volunteered. Ask about "huffing, bagging, dusting, whippets, poppers" by name. Peak prevalence is in early adolescence , and use often declines with age — the inverse of most substances.

Physical clues: perioral or perinasal rash ("glue sniffer's rash"), paint on hands or clothing, chemical odor on breath, frostbite burns, conjunctival injection.

Laboratory: basic metabolic panel with anion gap calculation, potassium, creatine kinase, liver enzymes, methylmalonic acid and homocysteine when nitrous oxide is suspected, methemoglobin level for nitrites, carboxyhemoglobin for methylene chloride. Routine urine drug screens do not detect inhalants .

Withdrawal: a mild syndrome (irritability, nausea, tremor, sleep disturbance) is described with heavy chronic solvent use but is not dangerous and requires only supportive care.

Treatment: no approved pharmacotherapy. Management is family-based and environmental — removing access, treating co-occurring conditions, addressing the developmental and social context, and family therapy. Prognosis is strongly tied to how quickly exposure stops, because the neurologic injuries do not reverse.